WindMIL Therapeutics is targeting marrow-infiltrating lymphocytes (MILs) to create a treatment to destroy cancer cells in patients, no matter their tumor type. By Laura Brzyski · 5/12/2021, 9:00 a.m.

BALTIMORE--(BUSINESS WIRE)--WindMIL Therapeutics, a clinical stage company developing Marrow-Infiltrating Lymphocytes (MILs™) for cancer immunotherapy, today announced the completion of a $32.5 ...

BALTIMORE and PHILADELPHIA, Dec. 12, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today ...

WindMIL Therapeutics Kimberly Noonan, PhD, MPH, WindMIL Therapeutics, Co-Founder and Executive Vice President, Chief Science & Technology Officer PHILADELPHIA and BALTIMORE, May 06, 2021 (GLOBE ...

PHILADELPHIA, BALTIMORE and OKLAHOMA CITY, Oct. 13, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and Stephenson Cancer Center today a ...

PHILADELPHIA and BALTIMORE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy ...

WindMil Therapeutics, a clinical-stage cancer immunotherapy company based in Baltimore, has opened a Philadelphia office to accommodate its expanding executive, operations and clinical teams.

WindMIL Therapeutics, a Baltimore-based company specializing in cell therapy to treat cancer, closed on $32.5 million in Series B funding, the company announced on Monday. The round was led by Qiming ...

WindMIL Therapeutics, a Baltimore-based cancer immunotherapy startup, has completed a $32.5 million Series B round led by Qiming Venture Partners USA.

WindMIL drew attention in June, when it closed a $32.5 million funding round. Along with the new location, the company is based in Johns Hopkins FastForward 1812, where its science team utilizes the ...

--WindMIL Therapeutics today announced it has entered into a new clinical research collaboration with Bristol-Myers Squibb Company to evaluate the safety and efficacy of WindMIL Therapeutics ...